Skip to content
RDL
Network
Ekosistem
Uygulama değiştir
EN
Hakkımızda
SSS
Giriş yap
Başla
Combination immunotherapy with anti-VEGF/TKI for hepatocellular carcinoma: present and future perspective — Masatoshi Kudo (2021) | RDL Network
Back
Cite
Save
Save for later
Share
Home
Publications
Combination immunotherapy with anti-VEGF/TKI for hepatocellular carcinoma: present and future perspective
Shared by
Masatoshi Kudo
Combination immunotherapy with anti-VEGF/TKI for hepatocellular carcinoma: present and future perspective
Article
2021
en
Authors
Masatoshi Kudo
Related publications
Editorial Material
2019
Combination Cancer Immunotherapy with Molecular Targeted Agents/Anti-CTLA-4 Antibody for Hepatocellular Carcinoma
Masatoshi Kudo
Article
2003
Hepatocellular carcinoma: present status and future prospects
Josep M. Llovet
,
Michel Beaugrand
Journal of Hepatology
Discussion
(0)
Sign in
to like and join the discussion.
No comments yet. Be the first to comment.
Editorial Material
2018
Combination Cancer Immunotherapy in Hepatocellular Carcinoma
Masatoshi Kudo
Editorial Material
2019
Scientific Rationale for Combination Immunotherapy of Hepatocellular Carcinoma with Anti-PD-1/PD-L1 and Anti-CTLA-4 Antibodies
Masatoshi Kudo
Editorial Material
2022
Combination Immunotherapy with Anti-PD-1/PD-L1 Antibody plus Anti-VEGF Antibody May Promote Cytotoxic T Lymphocyte Infiltration in Hepatocellular Carcinoma, Including in the Noninflamed Subclass
Masatoshi Kudo
Discussion(0)
No comments yet. Be the first to comment.